BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19293769)

  • 1. Breast cancer therapy: the role of PET-CT in decision making.
    Pons F; Duch J; Fuster D
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of / 18FDG PET/CT for the initial staging and therapy in primary breast cancer].
    Inokuchi M; Furukawa H; Kayahara M; Ohta T; Kawashima H; Taki J; Kinuya S
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2526-31. PubMed ID: 20009451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of PET-CT in the management of esophageal cancer.
    Chuang HH; Macapinlac HA
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):201-9. PubMed ID: 19293768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.
    Malone JP; Gerberi MA; Vasireddy S; Hughes LF; Rao K; Shevlin B; Kuhn M; Collette D; Tennenhouse J; Robbins KT
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1119-25. PubMed ID: 19917925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]FDG-PET-CT for early monitoring of tumor response: when and why.
    Storto G; Nicolai E; Salvatore M
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):167-80. PubMed ID: 19293765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
    Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
    Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography/computed tomography in locally advanced breast cancer.
    Ozkan E
    Exp Oncol; 2013 Dec; 35(4):253-7. PubMed ID: 24382434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular PET/CT imaging-guided radiation therapy treatment planning.
    Zaidi H; Vees H; Wissmeyer M
    Acad Radiol; 2009 Sep; 16(9):1108-33. PubMed ID: 19427800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET-CT for treatment planning in prostate cancer.
    Picchio M; Crivellaro C; Giovacchini G; Gianolli L; Messa C
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):245-68. PubMed ID: 19293771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications for PET/CT in the head and neck.
    Agarwal V; Branstetter BF; Johnson JT
    Otolaryngol Clin North Am; 2008 Feb; 41(1):23-49, v. PubMed ID: 18261525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
    Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
    J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental PET/CT findings in the cancer patient: how should they be managed?
    Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
    Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.